PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 22, 2026Journal of Pathology and Translational Medicine1 citationsOpen Access

HER2-low and ultralow breast cancer: interobserver challenges and lessons from a consensus study

JKJiwon KohYJYoon JinECEun Yoon Cho

Key Points

  • This study aims to evaluate the challenges in interpreting HER2-low and ultralow breast cancer statuses among experts.
  • Conducted a consensus study involving expert evaluation of HER2 status.
  • Analyzed discrepancies in the interpretation of HER2-low and ultralow designations.
  • Assessed the implications of defining HER2-null status.
  • Experts showed significant variability in identifying HER2-low and ultralow cases.
  • The necessity of distinguishing between HER2-low and ultralow was questioned.
  • Concerns about the clinical relevance of HER2-null breast cancer emerged.

Abstract

Experts had significant discrepancies in interpreting HER2-low/ultralow status. It is important to assess if the distinction between HER2-low and ultralow is strictly required and if HER2-null breast cancer exists in reality.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Koh et al. (2026) studied this question.

synapsesocial.com/papers/69bf8641f665edcd009e8c18https://doi.org/10.4132/jptm.2026.01.08
Ask AI
Helpful
Bookmark
Share
View Full Paper